I bet they get premium pay vs Rob G or Peso...
Did you get downsized from DNDN. Or someone get your prize job or credit? I could swear you were an employee all along. Maybe just a short all along. Sorry, investors don't flip from long fanatic to short on the news we heard today (little change in the news, if anything looking more positive).
Interesting! Spectrum also hired the VP sales from Dendreon TR last summer (confirmed). Cafepharma noted others in sales from DNDN following to Spectrum (unconfirmed).
Great that Yahoo removed the false post! Thanks imallin, havenger, and mtherami for calling out this poster early on the attempts to drum up fear with fake stories. This person needs help, to live on this board night and day to try to destroy the company's reputation and likely to induce selling.
Copied and pasted from this newsclip, then changed to Dendreon.
5:14p ET February 26, 2014 (Dow Jones)
Forest Oil Warns of Risk of Tripping Loan Covenants
By Katy Stech
Oil and natural gas driller Forest Oil Corp. (FST) warned investors Wednesday that it could fail to comply with requirements under one of its borrowing agreements, potentially causing roughly $800 million in bond debt to come due and forcing a bankruptcy filing.
Officials at the Denver-based company, which drills in Texas, Louisiana and Arkansas, said that they are trying to reach a deal with lenders that would help them stay within the loan's requirements, according to the company's annual report filed to the U.S. Securities and Exchange Commission.
The fine print of Forest Oil's loan agreements requires the 223-worker company to keep a certain ratio of debt to earnings after income, taxes and other costs--a ratio that could top "the maximum allowed [number] sometime during the second or third quarter of 2014," officials warned.
Without a deal with lenders, the company's bond debt could also become due and payable immediately.
"At worse, it could also result in foreclosure of our assets and potential bankruptcy," the company said in the regulatory filing.
A Forest Oil spokesman wasn't immediately available to comment.
The company said it could find new sources of money, including securing liens against properties or selling them, to pay for its operations. They could also slow some spending on new drilling projects to save money. But such cutbacks could have a "negative impact on our expected revenues, production and, potentially our reserves."
The announcement caused the company's bond prices to plummet. As of Dec. 31, the company had extended $577.9 million worth of notes due in 2019 and $222.1 million worth of notes due in 2020, according to the filing.
With roots tracing to 1916, Forest Oil said that it took in $441 million in revenue from oil, natural gas and natural gas liqu
You are right! Dendreon had approved patents for this pipeline product earlier in 2013. Search IV MB for TRPM8. The links from their website pipeline were deleted some time ago. Investor village has the timeline upon search.
Marie Huber, charged by SEC. Bought puts while degrading Provenge with the critique you included below which has been proven wrong by scientists. See IVMB and search for Huber. You'll find the sad, story of conflict of interest at it's finest! Hedge analyst publishes in a science journal about medicine! Inappropriate!
Unfortunately, Bass hasn't posted in a long time. Did he bail? I don't see 'Market Your Life" on IV MB either (posts similar content). I'm still holding, but this post doesn't say much if the poster is MIA.
Or see IV MB
NVS sold blood unit to Grifols for 1.7 billion in Nov, who subsequently gains shares of Tigenix in late Nov (owns 21%, 2nd shareholde Novartis ____). Now, in January we learn Tigenix is selling it's state of the art cell manufacturing facility to PharmaCell. PharmaCell is Dendreon's CMO in Europe since Oct 2013. Gained this from IV posts.
I was right on 'three.five" that he pumps before earnings. Now the dump. At least he admits it.
Thanks for posting. Important to track Phase III developments in this field; although this was for CNS tumors.
Provenge was first and first in these categories. No such thing as 'one of the first'. This means the 'second', but the NWBO CEO preferred to say 'one of the first'.
Add to this the high safety profile of Provenge relative to the other agents. The other agents are ezpensive as you mentioned, although no one bats an eyelash. Only Provenge was highlighted as costly. I believe this is partly due to early disbelief in immunoherapy for cancer and Huber's fraudulent actions which spread myths and falsehood gaining traction even to this day (Provenge search on Google still has a review of this article in the top page / 10 posts).
Phase II Bladder Cancer trial expected to be completed for final data collection primary endpoint June 2016. No longer recruiting, but still an active trial per 'clinicaltrials gov'. JJ said they would finish enrollment this month. They have an abstract for ASCO GU for prelim non-primary type data on this trial Jan 30 (or 31?). I would hope they might look at interim efficacy data and report at June ASCO. I'm not sure if this is feasible, but they sure are hiring several positions relative to labelling / safety / data / CMC manufacturing / FDA / EU / ICH documentation / analysis (if you read the job descriptions).